Clinical Trial Update: CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CD19-BCMA CAR T cell therapy for refractory lupus nephritis, systemic sclerosis, and primary Sjögren's syndrome with pulmo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Sjögren Syndrome with Pulmonary Hypertension
• Systemic Sclerosis

Drugs mentioned

• CD19/BCMA CAR-T Cell Therapy

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1, Phase 2 | Status: RECRUITING